CalciMedica, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

CALC$1.37-9.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(in thousands, except share amounts)

Common Stock · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’
	Shares	Amount	Capital	Deficit	Loss	Equity (Deficit)
Balance—January 1, 2026	3,087,348	$—	$182,685	$(189,326)	$—	$(6,641)
Stock-based compensation expense	—	—	561	—	—	561
Issuance of common stock from exercise of warrants	61,301	—	—	—	—	—
Vesting of restricted stock units	500	—	—	—	—	—
Net income	—	—	—	4,976	—	4,976
Balance—March 31, 2026	3,149,149	$—	$183,246	$(184,350)	$—	$(1,104)
Stock-based compensation expense	—	—	540	—	—	540
Issuance of common shares from private placement (net of issuance costs)	2,987,667	—	10,699	—	—	10,699
Issuance of warrants in connection with the private placement	—	—	3,000	—	—	3,000
Issuance of common stock from at-the-market offering (net of issuance costs)	9,822	—	31	—	—	31
Vesting of restricted stock units	500	—	—	—	—	—
Unrealized loss on investments	—	—	—	—	(1)	(1)
Net loss	—	—	—	(7,652)	—	(7,652)
Balance—June 30, 2026	6,147,138	$—	$197,516	$(192,002)	$(1)	$5,513
Stock-based compensation expense	—	—	496	—	—	496
Issuance of common shares from private placement (net of issuance costs)	—	—	(102)	—	—	(102)
Issuance of common stock from exercise of pre-funded warrants	747,011	1	(1)	—	—	—
Vesting of restricted stock units	500	—	—	—	—	—
Unrealized loss on investments	—	—	—	—	(6)	(6)
Net loss	—	—	—	(1,674)	—	(1,674)
Balance—September 30, 2026	6,894,649	$1	$197,909	$(193,676)	$(7)	$4,227

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(in thousands, except share amounts)

Common Stock · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’
	Shares	Amount	Capital	Deficit	Gain (Loss)	Equity (Deficit)
Balance—January 1, 2025	2,696,383	$—	$174,170	$(159,764)	$4	$14,410
Stock-based compensation expense	—	—	549	—	—	549
Issuance of common shares from underwritten public offering (net of issuance costs)	—	—	8	—	—	8
Issuance of common stock from at-the-market offering (net of issuance costs)	98,014	—	968	—	—	968
Unrealized loss on investments	—	—	—	—	(5)	(5)
Net loss	—	—	—	(5,042)	—	(5,042)
Balance—March 31, 2025	2,794,397	$—	$175,695	$(164,806)	$(1)	$10,888
Stock-based compensation expense	—	—	1,174	—	—	1,174
Unrealized loss on investments	—	—	—	—	(3)	(3)
Net loss	—	—	—	(5,956)	—	(5,956)
Balance—June 30, 2025	2,794,397	$—	$176,869	$(170,762)	$(4)	$6,103
Stock-based compensation expense	—	—	626	—	—	626
Issuance of common stock from at-the-market offering (net of issuance costs)	54,009	—	777	—	—	777
Issuance of common stock from exercise of stock options	3,037	—	25	—	—	25
Unrealized gain on investments	—	—	—	—	5	5
Net loss	—	—	—	(7,804)	—	(7,804)
Balance—September 30, 2025	2,851,443	$—	$178,297	$(178,566)	$1	$(268)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.